HBV genotypes and antiviral therapy of hepatitis B


  • I.A. Zaitsev Bogomolets National Medical University, Kyiv, Ukraine,
  • I.M. Novak Bogomolets National Medical University, Kyiv, Ukraine,
  • O.Ye. Zaitseva Bogomolets National Medical University, Kyiv, Ukraine,
  • V.T. Kiriienko Bogomolets National Medical University, Kyiv, Ukraine,




HBV infection, HBV genotype, HBV antiviral therapy, chronic hepatitis B


At least 600 thousand individuals infected with hepatitis B virus (HBV) die annually worldwide due to liver cirrhosis and hepatocellular carcinoma. To date, efficiency of antiviral therapy for HBV infection is limited, so the main goal of treatment is prevention of liver disease progression and not complete eradication of HBV. At the same time, special attention is paid not only to the study of new drugs, but also to the optimization of existing approaches and to the search for new strategies for treatment of chronic hepatitis B. In this regard, many scientific studies deal with the correlation between HBV genotypes, progression of chronic hepatitis B and response to antiviral therapy. There are 10 known HBV genotypes (A-J) that in different ways affect natural history of disease, response to antiviral therapy and development of drug resistance. An individualized approach to the treatment of HBV infection with determination of HBV genotype may allow to better predict liver disease progression and to optimize treatment strategies. This literature review summarizes results of scientific studies regarding the impact of HBV genotypes on response to antiviral therapy with pegylated interferon and nucleos(t)ide analogs.


Okamoto H., Tsuda F., Sakugawa H. et al. Typing hepatitis B virus by homology in nucleotide sequence. comparison of surface antigen subtypes. J. Gen. Virol. 1988. 69. 2575-2583.

Kramvis A., Kew M., Francois G. Hepatitis B virus genotypes. Vaccine. 2005. 23. 2409-2423.

Kramvis A., Kew M.C. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. Journal of Viral Hepatitis. 2005. 12. 456-464.

Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014. 57. 141-150.

Beck J., Nassal M. Hepatitis B virus replication. World Journal of Gastroenterology. 2007. 13. 48-64.

Junker-Niepmann M., Bartenschlager R., Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO Journal. 1990. 9. 3389-3396.

Малый В.П., Гололобова О.В., Лядова Т.И., Бойко В.В. Клинико-диагностическая характеристика генотипирования облигатно-гепатотропных вирусов. Влияние генотипов вирусов на клинические проявления и исходы болезни. Актуальная инфектология. 2013. 1 (1).

Yurchenko, Stepchenkova Т., Karnets I. et al. The results of a study on the prevalence of HIV, HCV and HBV genotypes in some regions of Ukraine. Retrovirology. 2012. 9 (Suppl 1). P. 55.

Ogawa M., Hasegawa K., Naritomi T. et al. Clinical features and viral sequences of various genotypes of hepatitis B virus compared among patients with acute hepatitis B. Hepatol Res. 2002. 23. 167-177

Suzuki Y., Kobayashi M., Ikeda K. et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J. Med. Virol. 2005. 76. 33-39 [PMID 15779048].

Sunbul M. Hepatitis B virus genotypes. Global distribution and clinical importance. World J. Gastroenterol. 2014 May 14. 20 (18). 5427-5434.

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017 Aug. 67 (2). 370-398.

Flink H.J., van Zonneveld M., Hansen B.E. et al. Treatment with Peg-interferon a-2b for HBeAg-positive chronic hepatitis B. HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol. 2006. 101. 297-303.

Buster E.H.C.J., Flink H.J., Cakaloglu Y. et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-posi­tive patients treated with peginterferon a-2b. Gastroenterology. 2008. 135. 459-467.

Wiegand J., Hasenclever D., Tillmann H.L. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from the explorative analysis of published evidence. Antivir. Ther. 2008. 13. 211-220.

Erhardt A., Ludwig A.D., Brunetto M. et al. HBV genotypes are the strongest predictors of response to interferon-alfa treatment. multivariate evaluation in 1229 hepatitis B patients [Abstract]. Hepatology. 2008. 48 (Suppl.). 700A.

Moura I.F., Lopes E.P., Alvarado-Mora M.V. et al. Phylogenetic analysis and subgenotypic distribution of the hepatitis B virus in Recife, Brazil. Infect. Genet. Evol. 2013. 14. 195-199

Boglione L., D’Avolio A., Cariti G. et al. Sequential thera­py with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J. Viral. Hepat. 2013. 20. e11-e19.

Zhang Y., Wu Y., Ye S. et al. The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo. Virus. Res. 2013. 171. 65-70.

Fan H.B., Guo Y.B., Zhu Y.F. et al. Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection. Hepat. Mon. 2012. 12. 333-338.

Kao J.H. Molecular epidemiology of hepatitis B virus. Korean J. Intern. Med. 2011. 26. 255-261.

Hou J., Schilling R., Janssen H.L.A. et al. Genetic chara­cteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J. Med. Virol. 2007. 79. 1055-1063.

Sugiyama M., Tanaka Y., Kato T. et al. Influence of he­patitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology. 2006. 44. 915-24.

Cho S.M., Choe B.H. Treatment strategies according to genotype for chronic hepatitis B in children. Ann. Transl. Med. 2016. 4 (18). 336.

Lampertico P., Viganò M., Cheroni C. et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013. 57. 890-896.

Sonneveld M.J., Rijckborst V., Cakaloglu Y. et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-posi­tive chronic hepatitis B patients treated with pegylated interferon-α2b. relation to response and HBV genotype. Antivir. Ther. 2012. 17 (1). 9-17.

Terrault N., Bzowej N., Chang K. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016. 63. 261-83.

Coffin C.S., Fung S., Ma M.M. Management of chronic hepatitis B. Canadian Association for the Study of the Liver consensus guidelines. Can. J. Gastroenterol. 2012. 26. 917-38.

Lin C.L., Kao J.H. The clinical implications of hepatitis B virus genotype. Recent advances. J. Gastroenterol. Hepatol. 2011. 26 Suppl 1. 123-130 [PMID 21199523. DOI: 10.1111/1440-1746].

Liu C.J., Kao J.H., Chen D.S. Therapeutic implications of hepatitis B virus genotypes. Liver. Int. 2005. 25. 1097-1107.

Kao J.H. Hepatitis B viral genotypes. clinical relevance and molecular characteristics. J. Gastroenterol. Hepatol. 2002. 17. 643-650.

Liu C.J., Kao J.H. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir. Ther. 2008. 13. 613-624.

Raimondi S., Maisonneuve P., Bruno S., Mondelli M. Is response to antiviral treatment influenced by hepatitis B virus genotype? Journal of Hepatology. 2010. 52. 441-449.

Marcellin P., Heathcote E.J., Buti M. et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008. 359. 2442-2455.

Liaw Y.F., Gane E., Leung N. et al. GLOBE Study Group. 2-Year GLOBE trial results. telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009. 136. 486-495.

Chan H.L., Chen Y.C., Gane E.J. et al. Randomized clinical trial. efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J. Viral. Hepat. 2012. 19. 732-43.

Kim J.M., Choe B.H., Chu M.A. et al. Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B. Korean J. Hepatol. 2009. 15. 168-78.

Zöllner B., Petersen J., Puchhammer-Stöckl E. et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology. 2004. 39. 42-50.

Hsieh T.H., Tseng T.C., Liu C.J. et al. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir. Ther. 2009. 14. 1157-63.

Westland C., Delaney W. 4th, Yang H. et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology. 2003. 125 (1). 107.

Fung S.K., Chae H.B., Fontana R.J. et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006. 44. 283.

Gish R.G., Chang T.T., Lai C.L. et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J. Viral. Hepat. 2010. 17. 16-22.

Saadah O.I., Sindi H.H., Bin-Talib Y. et al. Entecavir treatment of children 2–16 years of age with chronic hepatitis B infection. Arab. J. Gastroenterol. 2012. 13. 41-4.

Heathcote E.J., Marcellin P., Buti M. et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011. 140. 132-43.

Marcellin P., Ahn S.H., Ma X. et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology. 2016. 150. 134.